Vaccine Clinical Trials 2022

Browse 220 Vaccine Medical Studies Across 488 Cities
30 Phase 3 Trial · 1991 Vaccine Clinics

Display Results

All

Most EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials Vaccine Clinical Trials 2022

Reviewed by Michael Gill, B. Sc.

Image of Canadian Center for Vaccinology in Halifax, Canada.

Phase-Based Progress Estimates

Group G3, Subgroup G3-Afor COVID-19

Waitlist Available

VBI-2901e is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and MERS-CoV. The trivalent vaccine candidate is designed to induce neutralizing antibody and cell-mediated immune responses against the spike protein of the original strain of SARS-CoV-2 coronavirus, variants and subvariants of SARS-CoV-2 (such as Beta, Delta and Omicron BA.5) and other related coronaviruses that could emerge in the future. VBI-2901e contains two adjuvants: aluminum phosphate and E6020. The role of the adjuvants is to create a stronger immune response to the vaccine. This Phase 1 study will be an open-label study of VBI-2901e comparing three dose levels of the E6020 adjuvant component (1, 3, or 10 µg per dose) in adults 18 to 40 years of age who had previously received two or more vaccinations with licensed COVID-19 vaccine(s). VBI-2901e at each dose level of E6020 will be administered as either a single dose or two-dose regimen. The purpose of the study is to test the safety of VBI-2901e and to learn more about its ability to boost immune responses against SARS-CoV-2 and the two related coronaviruses SARS-CoV-1 and MERS-CoV.

Waitlist Available

Canadian Center for Vaccinology (+3 Sites)William Cameron, MDVBI Vaccines Inc.

Image of Canadian Center for Vaccinology in Halifax, Canada.

Phase-Based Progress Estimates

VBI-2901afor COVID19 (disease)

This trial is testing a vaccine candidate that uses particles to express the spike proteins of three coronaviruses: SARS-CoV-2, SARS-CoV-1, and MERS-CoV. The Phase 1 study will compare the safety of two doses of the vaccine candidate in adults 18-64 years old who have previously received two or more vaccinations for COVID-19. The purpose of the study is to test the safety of the vaccine candidate and to learn more about its ability to boost immunity against SARS-CoV-2 and the other two coronaviruses.

Canadian Center for Vaccinology (+6 Sites)William Cameron, MDVBI Vaccines Inc.

Image of Panax Clinical Research in Miami Lakes, United States.

Phase-Based Progress Estimates

CHIKV VLP/adjuvantfor Chikungunya Fever

Senior-friendly

This trial will test how safe and effective a new shingles vaccine is for adults aged 65 and over.

Senior-friendly

Panax Clinical Research (+9 Sites)Emergent BioSolutions

Image of Clinical and Translational Research Center (CTRC) at University of North Carolina (UNC) Hospitals and/or at UNC Global Clinical Research North in Chapel Hill, United States.

Phase-Based Progress Estimates

Meningococcal Group B Vaccinefor Gonorrhea

This trial tests whether the group B meningitis vaccine protects from Neisseria gonorrhoeae infection. Approximately 120-140 participants will be enrolled and receive 2 doses of vaccine.

Clinical and Translational Research Center (CTRC) at University of North Carolina (UNC) Hospitals and/or at UNC Global Clinical Research NorthJoseph A Duncan, MD, PhD

Image of Yale Health Plan in New Haven, United States.

Phase-Based Progress Estimates

Fluadfor Frailty

Waitlist Available

This trial will compare how well two different influenza vaccines work in adults over age 65.

Waitlist Available

Yale Health Plan (+1 Sites)Albert Shaw, MD, PhD

Image of Johnson County ClinTrials in Lenexa, United States.

Phase-Based Progress Estimates

CHIKV VLP/adjuvantfor Chikungunya Fever

Waitlist Available

This trial is testing a new vaccine to see if it is safe and effective.

Waitlist Available

Johnson County ClinTrials (+48 Sites)Patrick Ajiboye, MDEmergent BioSolutions

Image of Royal Inland Hospital in Kamloops, Canada.

Phase-Based Progress Estimates

Group 6: Pfizer/BioNTech, Pfizer/BioNTech - 112 Days Apartfor COVID-19

FDA Approved Drug

This trial is testing two different vaccines for safety and efficacy.

FDA Approved Drug

Royal Inland Hospital (+6 Sites)Joanne LangleyInterior Health

Image of Emory Vaccine Center - The Hope Clinic in Decatur, United States.

Phase-Based Progress Estimates

SAM-LNP-Sfor COVID-19

Waitlist Available

This trial is a phase 1 study to test the safety, tolerability, and immunogenicity of two investigational ChAd vaccines and two investigational SAM vaccines for COVID-19 in healthy adults in the US. The study will enroll 17 subjects in Stage 1 and up to 118 subjects in Stage 2. Subjects will be monitored for exposure and infection to SARS-CoV-2 throughout the study and followed for 12 months after their last vaccination.

Waitlist Available

Emory Vaccine Center - The Hope Clinic (+4 Sites)Gritstone bio, Inc.

Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Phase-Based Progress Estimates

Biospecimen Collectionfor Lymphoma, B-Cell

FDA Approved Drug

This trial will use an inactivated rabies virus vaccine to test immune function in patients who have undergone a new cancer treatment called CARTx. A group of healthy volunteers will also be enrolled to provide a comparison. CARTx is a new treatment for patients with cancer of the B-cells, and the long-term effects of CARTx on immune function are not yet well understood. This trial may help doctors better understand immune function and improve outcomes for this growing population of high-risk individuals.

FDA Approved Drug

Fred Hutch/University of Washington Cancer ConsortiumJoshua A. Hill

Image of University of Alabama at Birmingham in Birmingham, United States.

Phase-Based Progress Estimates

Fluzone Youngerfor Influenza, Human

FDA Approved Drug

This trial will look at how well different types of flu vaccines work in people of different ages, and whether previous vaccinations affect immunity.

FDA Approved Drug

University of Alabama at BirminghamJames J Kobie, PhD

Image of Washington University Siteman Cancer Center in Saint Louis, United States.

Phase-Based Progress Estimates

Pembrolizumabfor Prostate Cancer

FDA Approved Drug

This trial will evaluate the use of one versus two DNA vaccines to treat prostate cancer that has spread and is no longer responding to hormone therapy. The hypothesis is that delivering two vaccines with a drug that blocks PD-1 will increase the percentage of patients experiencing an anti-tumor effect.

FDA Approved Drug

Washington University Siteman Cancer Center (+1 Sites)Douglas McNeel, MD, PhDMerck Sharp & Dohme LLC

Image of Brigham and Women's Hospital in Boston, United States.

Phase-Based Progress Estimates

Rheum ICMPfor Lupus Erythematosus, Systemic

Waitlist Available

This study is evaluating whether a program can reduce acute care utilization and improve outcomes for lupus patients.

Waitlist Available

Brigham and Women's HospitalCandace H Feldman, MD, ScD

Image of AIDS Clinical Trials Unit/The Ohio State University in Columbus, United States.

Phase-Based Progress Estimates

A1DC + Inactivated Whole Autologous HIVfor HIV Infections

This trial will study an HIV vaccine made from a person's white blood cells. It will test safety, immune response, and compare four vaccine-making methods.

AIDS Clinical Trials Unit/The Ohio State University (+1 Sites)John Mellors, MD

Image of University of Virginia in Charlottesville, United States.

Phase-Based Progress Estimates

6MHPfor Melanoma

This trial is testing a new cancer vaccine with two different adjuvants to see if it is safe and if it boosts the immune response to the vaccine.

University of Virginia (+1 Sites)Craig L Slingluff, Jr., MDCelldex Therapeutics

Image of University of California, Los Angeles Neuro-Oncology Program in Los Angeles, United States.

Phase-Based Progress Estimates

VBI-1901for Glioblastoma Multiforme (GBM)

Waitlist Available

This trial will test a new drug, VBI-1901, on people with brain tumors to see if it is safe and effective.

Waitlist Available

University of California, Los Angeles Neuro-Oncology Program (+3 Sites)Francisco Diaz-Mitoma, MDVBI Vaccines Inc.

Image of Tom Baker Cancer Centre - Alberta Health Services in Calgary, Canada.

Phase-Based Progress Estimates

DPX-Survivacfor Recurrent

Waitlist Available

FDA Approved Drug

This trial is testing a new cancer treatment that consists of two priming doses of a 0.5 mL injection of DPX-Survivac, given 21 days apart, followed by up to six maintenance injections of 0.1 mL every two months for one year. The injections will be given with low-dose metronomic oral cyclophosphamide (50 mg twice daily) for one year or until disease progression, whichever occurs first. Pembrolizumab 200 mg will be administered every 3 weeks for up to one year or until disease progression, whichever occurs first.

Waitlist Available

FDA Approved Drug

Tom Baker Cancer Centre - Alberta Health Services (+5 Sites)Neil L Berinstein, MDImmunoVaccine Technologies, Inc. (IMV Inc.)

Image of The Sidney Kimmel Comprehensive Cancer at Johns Hopkins in Baltimore, United States.

Phase-Based Progress Estimates

Pembrolizumabfor Cancer of Pancreas

Waitlist Available

FDA Approved Drug

This trial will be testing a combination of drugs and radiation to treat pancreatic cancer.

Waitlist Available

FDA Approved Drug

The Sidney Kimmel Comprehensive Cancer at Johns HopkinsLei Zheng, MD, PhDMerck Sharp & Dohme LLC

Image of Adela Mahmutovic in Charlottesville, United States.

Phase-Based Progress Estimates

Trametinibfor Melanoma

FDA Approved Drug

This trial will see if it's safe to give a helper peptide vaccine with BRAF inhibitor and MEK inhibitor therapy, as well as if the combo affects the immune system. Blood and tumor tests will be done to monitor effects.

FDA Approved Drug

Adela Mahmutovic (+1 Sites)Elizabeth Gaughan, MD

Image of Memorial Sloan Kettering Cancer Center in New York, United States.

Phase-Based Progress Estimates

Langerhans-type Dendritic Cells (a.k.a. Langerhans Cells Or LCs)for Melanoma

Waitlist Available

This trial is being done to see if the investigators can help the immune system to work against melanoma by using dendritic cells.

Waitlist Available

Memorial Sloan Kettering Cancer CenterJames Young, MD

Image of Texas Children's Hospital in Houston, United States.

Phase-Based Progress Estimates

Neuroblastoma Vaccine (unmodified SKNLP, With Gene-modified SJNB-JF-IL2 And SJNB-JF-LTN Neuroblastoma Cellsfor Neuroblastoma

Waitlist Available

FDA Approved Drug

This trial is testing an experimental treatment for neuroblastoma, which is a solid tumor that is the second most common cancer in children. The treatment consists of a series of immunizations using a tumor vaccine, combined with low-dose chemotherapy taken by mouth on a daily basis. The hope is that the vaccine will cause the immune system to recognize and kill more types of neuroblastoma tumors. Additionally, the immunizations will be combined with daily low dose chemotherapy.

Waitlist Available

FDA Approved Drug

Texas Children's HospitalAndras A. Heczey, MD

Image of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, United States.

Phase-Based Progress Estimates

PNGVL4a-Sig/E7(detox)/HSP70 DNA Vaccinefor Precancerous Conditions

FDA Approved Drug

This trial is testing a new cancer vaccine and a cream to see if they can effectively treat cervical intraepithelial neoplasia.

FDA Approved Drug

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsCornelia L. Trimble, MD

Image of Dana-Farber Cancer Institute in Boston, United States.

Phase-Based Progress Estimates

Lethally Irradiated Lymphoma Cells With GM-CSF K562 Cellsfor Lymphoma

Waitlist Available

This trial is testing a new lymphoma vaccine to see if it is safe and if it boosts the immune system to better fight the cancer.

Waitlist Available

Dana-Farber Cancer InstituteEric Jacobsen, MD

Image of University of North Carolina in Chapel Hill, United States.

Phase-Based Progress Estimates

C62for HIV Vaccine

No Cost For Treatment

The purpose of this study is to evaluate whether intramuscular (IM) vaccination with C62-M4 or C1C62-M3M4 in persons with HIV-1 (PWH) on suppressive antiretroviral therapy (ART) will be safe and increase HIV-1-specific T cell responses targeting conserved regions of HIV-1.

No Cost For Treatment

University of North Carolina (+1 Sites)Nilu Goonetilleke, PhD

Image of GSK Investigational Site in Birmingham, United States.

Phase-Based Progress Estimates

Co-Ad Groupfor Respiratory Syncytial Virus Infections

The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65 years and above compared to separate administration of the vaccines.

GSK Investigational Site (+44 Sites)GlaxoSmithKline

Image of GSK Investigational Site in Norfolk, United States.

Phase-Based Progress Estimates

HPV9 Medium Formulationfor Cervical Intraepithelial Neoplasia

This trial is testing the safety of a new HPV vaccine.

GSK Investigational SiteGlaxoSmithKline

25 Vaccine Clinical Trials Near Me

Top Hospitals for Vaccine Clinical Trials

Image of Coastal Carolina Research Center in South Carolina.

Coastal Carolina Research Center

North Charleston

6Active Trials

0All Time Trials for Vaccine

2021First Vaccine Trial

Image of GSK Investigational Site in Texas.

GSK Investigational Site

San Antonio

6Active Trials

0All Time Trials for Vaccine

2016First Vaccine Trial

Top Cities for Vaccine Clinical Trials

Image of Miami in Florida.

Miami

42Active Trials

GSK Investigational SiteTop Active Site

Image of Houston in Texas.

Houston

37Active Trials

Texas Center for Drug Development, Inc.Top Active Site

Vaccine Clinical Trials by Phase of Trial

Phase < 1 Vaccine Clinical Trials

8Active Vaccine Clinical Trials

8Number of Unique Treatments

9Number of Active Locations

Trametinib Pneumococcal 13-valent Conjugate Vaccine Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine Neoadjuvant Chemotherapy Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine Anifrolumab Single Influenza Vaccine DKK1

Vaccine Clinical Trials by Age Group

< 18 Vaccine Clinical Trials

13Active Vaccine Clinical Trials

9vHPV Vaccine RSV vaccine formulation 2 Experimental: PIVOT with MI MenACYW conjugate vaccine Hepatitis B Vaccine Fluad Trivalent Influenza Vaccine RSV LID/ΔM2-2/1030s Sucrose RSV ΔNS2/Δ1313/I1314L Vaccine NU300 and Prevnar 13 Investigational RSV vaccine MV-012-968 (Dosage 2)RSV ΔNS2 Δ1313 I1314L Vaccine